Acorda Therapeutics (NSDQ:ACOR) submitted a marketing authorization application to the European Medicines Agency for its inhaled Parkinson’s disease therapy, Inbrija, according to the Ardsley, N.Y.-based company.
The investigational drug is designed to treat people with Parkinson’s disease who are experiencing “off” periods, or a re-emergence of symptoms.
Acorda’s marketing application for Inbrija includes data from a Phase III safety and efficacy trial and results from two long-term safety studies. The late-stage Phase III trial found that people with Parkinson’s disease experiencing “off” periods had statistically significant improvement in motor function after taking Inbrija.
The company is also hoping to land a regulatory win for its inhaled therapy in the U.S. Acorda resubmitted its new drug application for Inbrija in December last year and the FDA announced it would review the bid in February. The agency is set to make a decision regarding Inbrija by October.
ACOR shares were trading at $23.65 apiece in early-morning activity today, up +3.5%.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.